Investor Presentaiton
Investor Presentation
First six months of 2018.
Continued single digit volume growth within the insulin
segments globally
Slide 27
Fast-acting insulin
Segment volume
Premix insulin
Segment volume
NovoRapidⓇ market share
NovoMix® market share
Long-acting insulin
Segment volume
TresibaⓇ share
-
LevemirⓇ share
tMU
200
CAGR¹ volume: 5.6%
MI penetration: 78.3%
100%
tMU
200
CAGR¹ volume: 1.6%
MI penetration: 45.9%
100%
tMU
CAGR¹ volume: 6.5% 100%
200
MI penetration2: 83.3%
80%
80%
80%
160
160
160
- 60%
60%
60%
120
120
120
+40%
40%
40%
80
80
80
40
+ 20%
40
20%
40
20%
0%
0%
0
0%
May
2013
May
2018
May
2013
May
2018
May
May
2013
2018
1 CAGR for 5-year period. 2 Includes new-generation insulin. tMU: Thousand mega units
Note: Modern insulin (MI) penetration is of total segment, ie including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology
Source: IQVIA MAT May, 2018 volume figures
changing
diabetes
novo nordiskView entire presentation